Type: (null)
Journal: Oncotarget
Year: 2015
Pages: 6, 22496-22512
Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*
Distribution of the number of citations over years.

Authors

#AuthorsArticlesCitationsh-index
1Robert M Sharkey16293216